Actively Recruiting
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Led by Alliance Foundation Trials, LLC. · Updated on 2026-04-01
148
Participants Needed
21
Research Sites
310 weeks
Total Duration
On this page
Sponsors
A
Alliance Foundation Trials, LLC.
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
CONDITIONS
Official Title
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants with recurrent or persistent endometrial carcinoma that progressed after 1 to 2 prior therapy lines
- Measurable disease according to RECIST 1.1 criteria
- Availability of tumor tissue suitable for biomarker testing by FoundationOne CDx or approved alternative
- Life expectancy greater than 12 weeks
- Recovered from recent radiotherapy, surgery, or chemotherapy effects
You will not qualify if you...
- Endometrial tumors with squamous carcinoma or sarcoma histology
- Other invasive cancers within the last 5 years except certain treated skin or breast cancers
- Having synchronous primary invasive ovarian or cervical cancer
- Active or history of autoimmune disease or immune deficiency
- History of lung conditions like idiopathic pulmonary fibrosis or pneumonitis
- Active tuberculosis or severe infections within 4 weeks
- Recent therapeutic antibiotic use within 2 weeks, except prophylactic antibiotics
- Significant heart disease
- Recent live attenuated vaccine within 4 weeks or planned during study
- Prior bone marrow or solid organ transplant
- Recent treatment with systemic immunostimulatory or immunosuppressive drugs
- Untreated central nervous system disease, uncontrolled seizures, or recent stroke
- Prior treatment with immune checkpoint or T-cell costimulating therapies for AFT-50A cohort
- Additional cohort-specific criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Active, Not Recruiting
2
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94143
Active, Not Recruiting
3
Medstar Georgetown Cancer Institute
Washington D.C., District of Columbia, United States, 20007
Active, Not Recruiting
4
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140
Active, Not Recruiting
5
University of Chicago
Chicago, Illinois, United States, 60637
Active, Not Recruiting
6
University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Active, Not Recruiting
7
Maine Medical Center
Scarborough, Maine, United States, 04074
Active, Not Recruiting
8
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02125
Active, Not Recruiting
9
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Active, Not Recruiting
10
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri, United States, 63110
Withdrawn
11
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
Active, Not Recruiting
12
Englewood Health
Englewood, New Jersey, United States, 07631
Active, Not Recruiting
13
Atlantic Health Systems/Morristown Medical Center
Morristown, New Jersey, United States, 07960
Active, Not Recruiting
14
Roswell Park
Buffalo, New York, United States, 14263
Active, Not Recruiting
15
Weill Cornell Medicine
New York, New York, United States, 10065
Active, Not Recruiting
16
Duke University Cancer Center
Durham, North Carolina, United States, 27710
Active, Not Recruiting
17
University of Oklahoma Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
18
Providence Portland Cancer Institute
Portland, Oregon, United States, 97213
Active, Not Recruiting
19
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15261
Active, Not Recruiting
20
Lifespan - Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Active, Not Recruiting
21
Baptist Memorial Hospital
Memphis, Tennessee, United States, 38120
Withdrawn
Research Team
Q
Quality Management and Compliance
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here